884049-52-9

Usage

Uses

Due to the limited information provided, the specific applications of Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridin]-2'(1'H)-one are not clearly defined. However, given its complex structure and classification as an organic compound, it is likely to be used in the following areas:
Used in Chemical Research:
Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridin]-2'(1'H)-one may be employed as a research compound for studying its chemical properties, reactivity, and potential interactions with other molecules. Its unique structure could provide insights into new reaction pathways or mechanisms.
Used in Pharmaceutical Development:
Given the prevalence of complex ring systems in many pharmaceutical compounds, Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridin]-2'(1'H)-one could be utilized as a starting material or intermediate in the synthesis of novel drug candidates. Its potential biological activity and interactions with biological targets would need to be explored further.
Used in Material Science:
The unique structural features of Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridin]-2'(1'H)-one might also make it a candidate for the development of new materials with specific properties, such as conductivity, stability, or optical characteristics. Its potential applications in this field would depend on further research into its physical and chemical properties.

Upstream product

• 883984-92-7 3,4-dihydroxyspiro[cyclopent-3-ene-1,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 879132-48-6 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one 
• 879132-47-5 3,3-dibromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,3-dihydro-2H-pyrrolo[2.3-b]pyridin-2-one 
• 879132-46-4 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine 
• 271-63-6 7-Azaindole 
• 42330-59-6 (2-chloropyrid-3-yl)methanol 
• 89581-84-0 2-chloro-3-(chloromethyl)pyridine 
• 1315335-16-0 2-chloro-4'-cyano-3',4',5',6'-tetrahydro-2'H-[3,4']-bipyridinyl-1'-carboxylic acid tert-butyl ester 
• 885031-86-7 tert-butyl 2'-oxo-1',2'-dihydro-1H-spiro[piperidine-4,3'-pyrrolo[2.3-b]pyridine]-1-carboxylate 
• 1315335-15-9 N-Boc-4-(2-chloropyridin-3-yl)piperidine-4-carboxamide 
• 101012-32-2 2-(2-chloropyridin-3-yl)acetonitrile 
• 2942-59-8 2-chloronicotinic acid 
• 49609-84-9 2-Chloronicotinoyl chloride 
• 59-67-6 nicotinic acid 

Downstream Products

• 885031-86-7 tert-butyl 2'-oxo-1',2'-dihydro-1H-spiro[piperidine-4,3'-pyrrolo[2.3-b]pyridine]-1-carboxylate 

Relevant academic research and scientific papers

Conformationally constrained ortho- Anilino diaryl ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl) -3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist

Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 3l will also be presented. Compound 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.

A spirocyclic oxindole analogue: Synthesis and antitumor activities

A new synthesis of spirocyclic oxindole analogue spiro[piperidine-4, 3′-pyrrolo[2,3-b]pyridin]-2′(1′H)-one 1 is described. The key steps involve dialkylation of arylacetonitrile and cyclization of the azaoxindole ring by an intramolecular Buchwald-Hartwig amidation of carboxylic amide and aryl chloride. A small library was obtained by reductive amination of 1 with various aldehydes and was screened against human lung cancer cell A549, human liver cancer cell BEL7402, and human colon cancer cell HCT-8. The results show that most of the library compounds 2 have some inhibitory activities. 2-(Trifluoromethoxy) benzylic substituted spirocyclic azaoxindole 2e was identified as a nanomolar inhibitor against human lung cancer cell A-549 (IC50 = 50 nmol/L).

Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines

Several novel spiropiperidine-based CGRP receptor antagonists have been developed that maintain good potency and have reduced potential for metabolism.

HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (where variables R2, R7, D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula I and formula II (where variables D, R2, R4, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved,